Proposal to expand the Genovis Board of Directors at 2021 AGM

Report this content

The Nomination Committee proposes that Genovis should expand its Board of Directors at the 2021 Annual General Meeting and proposes Steve Jordan to be elected as a new board member.

Steve Jordan was born in 1953 and resides in the United Kingdom. He is currently working as a consultant for several companies engaged in development of new novel technologies and materials for the life science industries. Previous experiences include i.a. Chief Scientific Officer and Senior Director R&D Chemistry at Biotage during the years 2005-2020. Prior to that, Head of Business Development at CombiPure UK, Director Analytical of sciences, compound management and instrument development at Millennium UK and Section Leader for High Throughput Medicinal Chemistry at Roche Discovery Welwyn. Steve has no other board assignments and is independent in relation to the company, company management and the company's major shareholders.

The new Board of Directors in the proposal to the AGM is as follows: Re-election of Torben Jørgensen, Lotta Ljungqvist, Mikael Lönn and Kenth Petersson and new election of Steve Jordan.

The Nomination Committee proposes re-election of Torben Jørgensen to serve as Chairman of the Board.

Genovis’ Nomination Committee:

Mikael Lönn (Chairman)

TIN Fonder, represented by Erik Sprinchorn, Portfolio manager

Andra AP-fonden, represented by Johan Sjöström, Portfolio manager

Aktia Fondbolag AB, represented by Markus Lindqvist, Director, Aktia Kapitalförvaltning AB 

For more information, please contact:

Mikael Lönn, Chairman of the Nomination Committee | +46 (0)70-679 13 13 |

Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company’s Certified Adviser,, T: +46 (0)8-463 83 00.

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail. 


Documents & Links